Impel NeuroPharma Inc:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10620)
◆英語タイトル:Impel NeuroPharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10620
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delivery technology, a nasal drug delivery platform that delivers drugs for improved biodistribution. Impel’s products are used for the treatment of pain, depression, bipolar disorder, Alzheimer’s disease, migraine and Parkinson’s disease, among others. The company serves pharmaceutical and biotechnology companies, and premier academic research institutions. Impel is headquartered in Seattle, Washington, the US.

Impel NeuroPharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 11
Impel NeuroPharma Raises USD22.3 Million in Venture Financing 12
Impel NeuroPharma Raises USD0.08 Million in Venture Financing 13
Impel Neuropharma Raises US$2.6 Million In Venture Financing 14
Partnerships 15
Impel NeuroPharma and Camargo Pharma Enter into Agreement 15
3M Drug Delivery Systems Enters into Agreement with Impel NeuroPharma 16
Licensing Agreements 17
Centre for Addiction and Mental Health Enters into Licensing Agreement with Impel NeuroPharma 17
Impel NeuroPharma Inc – Key Competitors 18
Impel NeuroPharma Inc – Key Employees 19
Impel NeuroPharma Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Nov 07, 2018: Impel NeuroPharma names Ellen A. Lubman as chief business officer 21
Oct 03, 2017: Impel NeuroPharma Board Announces Appointment of Jon Congleton as CEO 22
Mar 03, 2017: Veteran Biotech Executive Timothy S. Nelson Joins Impel’s Board of Directors 23
Clinical Trials 24
May 31, 2018: Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson’s Disease OFF Episodes 24
Feb 07, 2018: Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache 25
Oct 31, 2017: Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache 26
Other Significant Developments 27
Feb 07, 2017: Impel NeuroPharma Partners with Camargo Pharmaceutical Services for Development Programs 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 11
Impel NeuroPharma Raises USD22.3 Million in Venture Financing 12
Impel NeuroPharma Raises USD0.08 Million in Venture Financing 13
Impel Neuropharma Raises US$2.6 Million In Venture Financing 14
Impel NeuroPharma and Camargo Pharma Enter into Agreement 15
3M Drug Delivery Systems Enters into Agreement with Impel NeuroPharma 16
Centre for Addiction and Mental Health Enters into Licensing Agreement with Impel NeuroPharma 17
Impel NeuroPharma Inc, Key Competitors 18
Impel NeuroPharma Inc, Key Employees 19

List of Figures
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Impel NeuroPharma Inc:製薬・医療:M&Aディール及び事業提携情報(Impel NeuroPharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆